Study guide

Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

Key Takeaways Explain This Topic AI

Immune-related adverse events can affect any organ and may appear weeks to months after checkpoint-inhibitor therapy ends; high-grade events are treated by holding the drug and giving corticosteroids.

Cytokine release syndrome (CRS) is graded by the ASTCT consensus on fever, hypotension, and hypoxia; tocilizumab is the targeted therapy for significant CRS.

ICANS severity is scored with the 10-point Immune Effector Cell-Associated Encephalopathy (ICE) tool, where 7 to 9 is grade 1, 3 to 6 is grade 2, 0 to 2 is grade 3, and 0 with an unarousable patient is grade 4.

Fever is the earliest and defining sign of CRS, and any fever after CAR T-cell or bispecific-antibody therapy is treated as urgent until CRS and infection are excluded.

Patients must carry a wallet card with their cell-therapy product and date, avoid driving during restricted periods, and report fever, confusion, tremor, or speech change immediately.

Last updated: June 2026

Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

Immune therapies keep working after the infusion ends - both their benefit and their danger. Checkpoint inhibitors, CAR T-cell therapy, bispecific antibodies, and cytokines cause inflammatory toxicity that overlaps with infection, progression, embolism, and endocrine failure. The RN triage question is: could this symptom be immune-related and urgent?

Immune-Related Adverse Events

Immune-related adverse events (irAEs) from checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) can strike skin, bowel, liver, lungs, kidneys, endocrine glands, heart, or nerves, and may appear weeks to months after therapy ends .

  • Syndrome Urgent clues
  • Pneumonitis Cough, dyspnea, hypoxia
  • Colitis Frequent diarrhea, blood, pain, dehydration
  • Hepatitis Jaundice, dark urine, high transaminases
  • Myocarditis Chest pain, dyspnea, palpitations, syncope
  • Endocrine crisis Hypotension, severe fatigue, vomiting, confusion

Immune-related myocarditis is rare but carries high mortality and must be escalated immediately. The cornerstone of management for moderate-to-severe irAEs is to hold the immunotherapy and start corticosteroids , with hormone replacement for endocrinopathies (which often is permanent). A key safety rule: do not tell patients to self-start steroids or antidiarrheals unless that is their specific plan from the oncology team.

Cytokine Release Syndrome

Cytokine release syndrome (CRS) is a systemic inflammatory response most associated with CAR T-cell therapy and bispecific antibodies . Fever (38.0 C or higher) is the defining first sign. The ASTCT consensus grading scales CRS by fever plus hypotension and hypoxia:

  • CRS grade Hypotension Hypoxia
  • 1 None None
  • 2 Responds to fluids Low-flow oxygen needed
  • 3 Needs one vasopressor High-flow oxygen needed
  • 4 Multiple vasopressors Positive-pressure ventilation

CRS can look exactly like sepsis, and both are treated urgently while the cause is sorted out. Nursing actions: frequent vitals, continuous pulse oximetry, mental-status checks, intake and output, telemetry, cultures and antibiotics if infection is possible, and rapid notification. Tocilizumab (an IL-6 receptor blocker) is the targeted therapy for significant CRS, with corticosteroids, fluids, oxygen, and vasopressors as needed. Treat any fever after cellular therapy or a bispecific antibody as urgent until the team says otherwise.

ICANS and the ICE Score

Immune effector cell-associated neurotoxicity syndrome (ICANS) is neurotoxicity after immune-effector therapy. Early signs are subtle: handwriting change, word-finding difficulty, tremor, slowed responses, impaired attention, or mild confusion. Severe ICANS brings aphasia, somnolence, seizures, motor weakness, cerebral edema, and coma. Grade it with the 10-point Immune Effector Cell-Associated Encephalopathy (ICE) tool : orientation to year, month, city, hospital (4 points); naming 3 objects (3 points); following a command (1 point); writing a standard sentence (1 point); and attention by counting backward from 100 by 10 (1 point).

  • ICE score ICANS grade
  • 7 to 9 Grade 1
  • 3 to 6 Grade 2
  • 0 to 2 Grade 3
  • 0 and unarousable Grade 4

A falling ICE score, declining consciousness, seizure, or cerebral edema raises the grade. Implement seizure and fall precautions, assess swallowing and airway, avoid sedating medications unless ordered, and escalate any change. ICANS may follow CRS or appear independently.

Urgent Triage and Education

Effective triage starts by identifying the therapy - ask for the treatment card, product name, infusion or step-up date, and emergency instructions. Triage conservatively: a fever after a bispecific antibody is not just a fever until CRS and infection are considered; new confusion after CAR T-cell therapy is not fatigue until ICANS, sepsis, and metabolic causes are ruled out. Teach patients to carry their wallet card, avoid driving during the restricted period after cellular therapy, stay near the treating center if instructed, and call immediately for fever, dizziness, dyspnea, confusion, tremor, speech change, or seizure.

Caregivers are essential observers - include them in every teaching session and handoff, which should list the product, date and cycle, time from infusion, baseline neuro status, vital-sign trends, and whether the cell-therapy team has been contacted.

Timing, Overlap, and the Conservative Mindset

Timing is a powerful triage clue across these immune emergencies. CRS typically begins within the first several days after CAR T-cell infusion, and ICANS often follows CRS, frequently peaking a few days later, though either can occur alone. Checkpoint-inhibitor irAEs behave differently - they can appear after a single dose or emerge months into therapy and even after it stops, so a patient presenting to the emergency department with new colitis or hepatitis weeks after immunotherapy may not connect the symptom to the drug unless the nurse asks.

Always reconstruct the treatment timeline: product, last dose, step-up status, and any restricted activity period.

The disciplined mindset for immune emergencies is conservative escalation, because early symptoms are easy to mislabel and the consequences of missing them are severe. A low-grade fever after a bispecific antibody is CRS until infection is excluded; new word-finding trouble after cellular therapy is ICANS until proven otherwise; new diarrhea after a checkpoint inhibitor is immune colitis until infection and dehydration are assessed; and chest pain or new dyspnea after immunotherapy must raise myocarditis, which can be fatal.

The nurse's job is not to grade or name the syndrome alone but to recognize the pattern, apply the validated tools such as ICE scoring, and bring the cell-therapy or immunotherapy team to the bedside fast, with caregivers engaged as essential observers throughout.